First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Vivani Medical, Inc.

    VANI · 10 developments mapped · last assessed 2026-08-31

    Market Ontology has mapped 10 macro, policy, and market developments to Vivani Medical, Inc. since 2026-08-30. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for VANI yet, so no modelled value is shown. The VANI valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run VANI on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for VANI. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Novo Nordisk Introduces Oral Wegovy and Vivani Implant Partnership

      Direct partnership with a major pharmaceutical company for a key product, validating technology and providing potential future revenue streams.

      · Moves technology validation and adoption, future licensing or milestone payments, ability to secure additional partnerships

    What changed, by assumption

    Probability of success for pipeline products
    • 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 Implants
    • 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani on Implant Delivery
    • 2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly Lead
    Technology validation and adoption
    • 2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant Partnership
    Probability of clinical success for pipeline products
    • 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Implant Delivery in GLP-1 Race
    Technology validation and commercialization potential
    • 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery Partnership
    Probability of success for lead programs
    • 2026-08-30Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 Implant

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-07-07Valuation multipleBullishTarget re-rates to bid premium until close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly LeadBullish1-5y0.60
    2026-08-31Novo Nordisk advances Wegovy pill formulation and Vivani implant partnershipBullish3-12m0.70
    2026-08-31Novo Nordisk advances oral Wegovy and Vivani implant partnership in GLP-1 raceBullish1-5y0.70
    2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant PartnershipBullish1-3m0.90
    2026-08-30Novo Nordisk Introduces Wegovy Pill and Partners on Long-Acting ImplantBullish3-12m0.70
    2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Implant Delivery in GLP-1 RaceBullish3-12m0.90
    2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 ImplantsBullish3-12m0.90
    2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery PartnershipBullish3-12m0.90
    2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani on Implant DeliveryBullish1-5y0.70
    2026-08-30Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 ImplantBullish1-5y0.90